Related Experiment Videos
[Treatment of transformed refractory migraine with intravenous dihydroergotamine]
C Cid1, F Ortega-Valín, M Valero
1Servicio de Neurología, Hospital Universitario Marqués de Valdecilla, Santander.
Abstract:
In this work we present our experience with a seven-day protocol of i.v. dihydroergotamine (DHE) in the treatment of 6 patients (7 treatments) suffering from intractable transformed migraine. All of them were admitted to hospital and treated for one week with a protocol which included DHE doses between 0.5-1 mg/8 h. One patient did not respond. The remaining 6 became free of pain in under 48 hours after the beginning of treatment. This positive effect remained for between 15 days and 3 months. All patients experienced adverse events; however, these were slight and ceased when the DHE dose was reduced. DHE is an effective and quick option for the short-term treatment of patients with severe transformed migraine resistant to other medications.